1. Introduction {#s1}
===============

Coronary chronic total occlusion (CTO) is found about 15%--30% of patients undergoing diagnostic coronary angiography.[@b1],[@b2] Compared to non-CTO lesion, the success rates of CTO lesion is much lower (\> 98% *vs.* 50%--88%).[@b3] Several factors may be attributable to this relatively low success rates, including technical complexity such as inability for guidewire crossing, high risks of serious complications during and after the procedure and requirement of skilled operators.[@b4] However, successful CTO percutaneous coronary intervention (PCI) can improve quality of life and left ventricular systolic function, and reduce ischemia.[@b5],[@b6] Several studies[@b7],[@b8] had showed acceptable mid-term to long-term survival outcomes after successful CTO PCI.

Compared to plain old balloon angioplasty (POBA), bare-metal stents (BMS) implantation showed better outcomes.[@b9] The first-generation (1G) drug-eluting stents (DES) such as Sirolimus-eluting stents (SES) or Paclitaxel-eluting stents (PES) were also associated with reductions in angiographic target vessel revascularization (TVR) and major adverse cardiac events (MACE) compared with BMS.[@b10],[@b11] Therefore, in present "real world" practice, BMS was replaced by DES because its anti-proliferative and anti-inflammatory characteristics.[@b12] Many data suggested that DES can enhance long-term patency rates and freedom from restenosis and repeated revascularization compared with BMS in patients with CTO.[@b9] Recently several studies showed clinical outcomes comparison between 1G-DES and second-generation (2G)-DES \[Zotarolimus-eluting stent (ZES) or Everolimus-eluting stent (EES)\].[@b13]--[@b15] But these studies showed relatively short-term or mid-term outcomes (three years)[@b16] compared with our study. Thus, we investigated the 5-year long-term major clinical outcomes between 1G-DES and 2G-DES in patient with CTO lesions underwent successful CTO PCI.

2. Methods {#s2}
==========

This study is a single-center, prospective, all-comer registry designed to reflect the "real world" practice from January 2004 to November 2015. Data were obtained from CTO registry of Korea University Guro Hospital (KUGH), Seoul, South Korea and collected by trained study-coordinators with a standardized case report form. The study protocol was approved by Medical Device Institutional Review Board of KUGH according to the ethical guidelines of the 1975 Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study prior to enrollment.

2.1. Study population {#s2a}
---------------------

A total of 4909 consecutive patients were diagnosed with significant coronary artery disease (≥ 70% of coronary stenosis) by coronary angiogram. Among these patients, 840 patients (17.1%) had CTO on the coronary main vessels. Exclusion criteria were optimal medical treatments (*n* = 410), previous coronary artery bypass graft (*n* = 12), history of cardiogenic shock or cardiopulmonary resuscitation (*n* = 7), failed PCI (*n* = 40), POBA (*n* = 13), other kinds of stents implantation except for SES, PES, ZES, and EES (*n* = 47), stent size required to treat lesion \> 3.5 mm (maximum diameter of SES, *n* = 14), and not participate or follow-up loss (*n* = 15). Finally, a total of 324 eligible CTO patients who underwent PCI with 1G-DES (SES: *n* = 54 or PES: *n* = 103, total *n* = 157) or 2G-DES (ZES: *n* = 126 or EES: *n* = 41, total *n* = 167) were enrolled. After propensity score-matching (PSM) analysis, two PSM groups (222 pairs, *n* = 111) were generated ([Figure 1](#jgc-16-08-639-g001){ref-type="fig"}). After PSM analysis, in the 1G-DES, 33% of the vessels treated with SES (*n* = 37), the other 67% of the vessels treated with PES (*n* = 74). In the 2G-DES group, 80% of the vessels were treated with ZES (*n* = 88) and 20% of the vessels treated with EES (*n* = 23).

![Flow chart.\
\*Other kinds of stents except for sirolimus-eluting stent, paclitaxel-eluting stent, zotarolimus-eluting stent or everolimus-eluting stent. CABG: coronary artery bypass graft; CPR: cardiopulmonary resuscitation; CTO: chronic total occlusion; OMT: optimal medical treatment; PCI: percutaneous coronary intervention; POBA: plain old balloon angioplasty; SES: sirolimus-eluting stent; 1G-DES: first-generation drug-eluting stents; 2G-DES: second-generation drug-eluting stents.](jgc-16-08-639-g001){#jgc-16-08-639-g001}

2.2. PCI procedure and medical treatment {#s2b}
----------------------------------------

A diagnostic coronary angiography and PCI were done through either the femoral or radial artery after an administration of unfractionated heparin (70--100 IU/kg). Patient\'s activated clotting time was maintained above 250 seconds during the procedure. All patients received a loading dose of 200 to 300 mg aspirin and 300 to 600 mg of clopidogrel as the dual antiplatelet regimen and maintained with 100 mg of aspirin and 75 mg of clopidogrel. After stent implantation, dual antiplatelet therapy (100 mg daily aspirin and 75 mg daily clopidogrel) was prescribed for at least 12 months. During hospitalization period, all the enrolled patients had taken cardiovascular beneficial medications, including beta-blockers, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers, calcium channel blockers, and lipid lowering agents. After discharge, the patients were encouraged to stay on the same medications they received during hospitalization.

2.3. Study deﬁnitions and clinical follow-up {#s2c}
--------------------------------------------

CTO is defined as a complete obstruction of the coronary vessel with thrombolysis in myocardial infarction (TIMI) flow grade 0 for at least three months.[@b1] A successful PCI was deﬁned as the achievement of an angiographic residual stenosis than 30% and final TIMI blood ﬂow grade 3 on CTO vessel. The coronary main vessels was defined as coronary vessels with reference vessel diameter (RVD) \> 2.5 mm and CTO must be located on the main vessel at left main, left anterior descending, left circumflex, right coronary and ramus artery.[@b17],[@b18] Patients were excluded if they had any CTO in small vessels (RVD ≤ 2.5 mm) located on the side branch vessels such as an acute marginal, diagonal, septal and obtuse marginal artery. We defined the primary endpoint was the cumulative occurrence of MACE up to 5-years. MACE was defined as the composite of all-cause death, recurrent myocardial infarction (re-MI), total repeat revascularization {target CTO-lesion \[target lesion revascularization (TLR), TLR-CTO vessel\], target CTO-vessel \[target vessel revascularization (TVR), TVR-CTO vessel\], and non-CTO vessel revascularization (non-TVR, non-TVR-CTO vessel)}. All-cause death was classified as cardiac or non-cardiac death. Re-MI was deﬁned as the presence of clinical symptoms, electrocardiographic changes, or abnormal imaging findings of MI, combined with an increase in the creatine kinase myocardial band fraction above the upper normal limits or an increase in troponin-T/troponin-I to greater than the 99^th^ percentile of the upper normal limit. TLR was deﬁned as a revascularization of the target CTO lesion due to restenosis or reocclusion within the stent or 5 mm in and adjacent of the distal or proximal CTO segment. TVR was deﬁned as a revascularization of the target CTO vessel or any segment of the coronary artery containing the target CTO lesion. Non-TVR was defined as a revascularization of any segment of the non-target CTO coronary artery. The recording of cardiovascular risk factors and past medical histories were based on patients\' self-report. All participants were required to visit the outpatient department of cardiology at the end of the ﬁrst month and then every three to six months after the index CTO PCI procedure and we could follow up on the clinical data of all enrolled patients through face-to-face interviews at regular outpatient clinic, medical chart reviews, and telephone contacts.

2.4. Statistical analysis {#s2d}
-------------------------

For continuous variables, differences between the two groups were evaluated with the unpaired *t*-test or Mann-Whitney rank test. Data were expressed as mean ± SD. For discrete variables, differences were expressed as counts and percentages and analyzed with *χ*^2^ or Fisher\'s exact test between the groups as appropriate. To adjust for any potential confounders, PSM analysis was performed using the logistic regression model. We tested all available variables that could be of potential relevance: gender (men), age, systolic blood pressure, left ventricular ejection fraction, ST-segment elevation myocardial infarction (STEMI), non-STEMI, cardiovascular diseases risk factors (hypertension, diabetes, dyslipidemia, chronic kidney disease, cerebrovascular accident, peripheral vascular disease, previous history of MI, previous history of PCI, current smoker), laboratory findings (*i.e.*, creatine kinase myocardial band, troponin T, high-sensitivity C-reactive protein, lipid profiles and serum creatinine), angiographic and procedural characteristics. The PSM analysis was estimated with the use of C-statistic for the logistic regression model (C-statistics = 0.718). Patients in the 1G-DES group were then one-to-one matched to those in the 2G-DES group according to propensity scores with the nearest available pair matching method. Subjects were matched with a caliper width equal to 0.01. Between the two groups were compared with the log-rank test. Proportional hazard models were used to assess the hazard ratio of the 1G-DES group compared with the 2G-DES group adjusted propensity score. For all analyses, a two-sided *P*-value of \< 0.05 was considered statistically significant. All data were processed with SPSS (version 20.0, SPSS-PC, Inc. Chicago, Illinois).

3. Results {#s3}
==========

[Table 1](#jgc-16-08-639-t01){ref-type="table"} shows baseline, angiographic and procedural characteristics of the study population. Before PSM adjustment, the mean age of the 1G-DES group was 60.2 ± 10.6 years and 2G-DES was 62.0 ± 10.5 years (*P* = 0.123). Gender distribution (men) was also similar between the two groups (74.5% *vs.* 78.4%, *P* = 0.405). The numbers of dyslipidemia (33.8% *vs.* 22.8%, *P* = 0.028) and current smokers (51.6% *vs.* 29.3%, *P* \< 0.001) were significantly higher in the 1G-DES group. The numbers of Rentrop collateral grade I patients were higher in the 1G-DES (27.4% *vs.* 13.8%, *P* = 0.002) but Rentrop collateral grade II patients were higher in the 2G-DES (31.8% *vs.* 52.7%).[@b19] The number of multivessel disease was higher in 2G-DES compared to 1G-DES (62.3% *vs.* 45.9%, *P* = 0.003). [Table 2](#jgc-16-08-639-t02){ref-type="table"} shows clinical outcomes such as, MACE, all-cause death, cardiac death, non-fatal MI, total repeat revascularization \[TLR-CTO vessel, TVR-CTO vessel, non-TVR (non-CTO vessel)\] by Cox-proportional hazards ratio analysis and Kaplan-Meir curved analysis up to five years. Before and after PSM, the cumulative incidences of MACE, all-cause death, MI, total repeat revascularization, TLR-CTO vessel, TVR-CTO vessel, and non-TVR-CTO vessel were similar between the two groups. [Figure 2](#jgc-16-08-639-g002){ref-type="fig"} shows Kaplan-Meier curved analysis of MACE, TLR-CTO vessel, TVR-CTO vessel up to 5-year according to the generation of DES (1G-DES *vs.* 2G-DES) and types of DES (SES *vs.* PES *vs.* ZES *vs.* EES) after PSM.

###### Baseline and angiographic characteristics.

  Variables                                      Entire patients   Propensity score-matched patients                                             
  --------------------------------------------- ----------------- ----------------------------------- ---------- --------------- --------------- -------
  Gender, men                                      117 (74.5%)                131 (78.4%)               0.405      86 (77.5%)      83 (74.8%)     0.637
  Age, yrs                                         60.2 ± 10.6                62.0 ± 10.5               0.123      61.1 ± 10.0     61.6 ± 10.9    0.749
  Systolic blood pressure, mmHg                   144.0 ± 26.6               141.1 ± 21.3               0.285     144.0 ± 24.6    141.8 ± 20.0    0.455
  LVEF                                            50.1% ± 10.6%              51.5% ± 12.7%              0.294     50.9% ± 10.0%   51.6% ± 12.8%   0.698
  ST segment elevation MI                          19 (12.1%)                  11 (6.6%)                0.087       6 (5.4%)        7 (6.3%)      0.775
  Non-ST segment elevation MI                      24 (15.3%)                 19 (11.4%)                0.300      14 (12.6%)      15 (13.5%)     0.842
  Hypertension                                     97 (61.8%)                 107 (64.1%)               0.670      71 (64.0%)      59 (62.2%)     0.781
  Diabetes mellitus                                56 (35.7%)                 66 (39.5%)                0.474      41 (36.9%)      40 (36.0%)     0.889
  Dyslipidemia                                     53 (33.8%)                 38 (22.8%)                0.028      27 (24.3%)      30 (27.0%)     0.645
  Chronic kidney disease                            10 (6.4%)                  14 (8.4%)                0.489       5 (4.5%)        9 (8.1%)      0.269
  Cerebrovascular accident                          9 (5.7%)                   15 (9.0%)                0.264       9 (8.1%)        10 (9.0%)     0.810
   Ischemic stroke                                  6 (3.8%)                   11 (8.7%)                0.087       6 (5.4%)        9 (9.9%)      0.226
   Hemorrhagic stroke                               3 (1.9%)                   4 (3.1%)                 0.503       3 (2.7%)        1 (1.1%)      0.416
  Peripheral vessel disease                         8 (5.1%)                   15 (9.0%)                0.173       7 (6.3%)        4 (3.6%)      0.354
  Previous MI                                      26 (16.6%)                 27 (16.2%)                0.924      19 (17.1%)       11 (9.9%)     0.116
  Previous PCI                                     38 (24.2%)                 36 (21.6%)                0.571      25 (22.5%)      17 (15.3%)     0.170
  Current smoker                                   81 (51.6%)                 49 (29.3%)               \< 0.001    50 (45.0%)      40 (36.0%)     0.172
  CK-MB, mg/dL                                     12.2 ± 32.4                9.8 ± 24.5                0.462      11.2 ± 29.7     11.6 ± 28.4    0.919
  Troponin T, ng/dL                                0.24 ± 0.81                0.13 ± 0.28               0.254      0.11 ± 0.43     0.18 ± 0.66    0.410
  High sensitivity CRP, mg/dL                       1.8 ± 5.0                  2.2 ± 8.0                0.628       1.5 ± 5.1       2.7 ± 9.0     0.300
  Total cholesterol, mg/L                         164.9 ± 39.0               168.1 ± 41.4               0.508     163.9 ± 40.1    168.5 ± 35.2    0.401
  Triglyceride, mg/L                              146.6 ± 78.4               143.0 ± 97.0               0.737     146.5 ± 77.2     145.4 ± 102    0.936
  HDL cholesterol, mg/L                            44.5 ± 32.5                42.2 ± 11.4               0.436      45.3 ± 38.9     43.4 ± 11.5    0.650
  LDL cholesterol, mg/L                           110.1 ± 36.7               105.6 ± 38.3               0.344     108.8 ± 35.4    105.6 ± 35.9    0.560
  Serum creatinine, mg/L                           1.28 ± 1.54                1.23 ± 1.25               0.762      1.16 ± 0.65     1.18 ± 1.23    0.885
  Angiographic and Procedural characteristics                                                                                                    
   Multivessel disease                             72 (45.9%)                 104 (62.3%)               0.003      56 (50.5%)      54 (48.6%)     0.788
   Number of CTO vessels                           1.10 ± 0.30                1.09 ± 0.31               0.954      1.07 ± 0.26     1.05 ± 0.25    0.429
   CTO lesion artery                                                                                                                             
    Left anterior descending                       66 (42.0%)                 68 (40.7%)                0.810      41 (36.9%)      49 (44.1%)     0.274
    Left circumflex                                43 (27.4%)                 45 (26.9%)                0.929      35 (31.5) %     27 (24.3%)     0.231
    Right coronary artery                          63 (40.1%)                 69 (41.3%)                0.828      44 (39.6%)      42 (37.8%)     0.783
    Ramus                                           0 (0.0%)                   1 (0.6%)                 0.331       0 (0.0%)        0 (0.0%)       \-
    No of multivessel CTO (≥ 2 vessels)             15 (9.6%)                  14 (8.4%)                0.536      12 (10.8%)       5 (4.5%)      0.077
   Location of CTO lesion                                                                                                                        
    Proximal                                       70 (44.6%)                 85 (50.9%)                0.256      48 (43.2%)      51 (45.9%)     0.685
    Mid                                            72 (45.9%)                 67 (40.1%)                0.297      50 (45.0%)      50 (45.0%)     1.000
    Distal                                          15 (9.6%)                  15 (9.0%)                0.859      13 (11.7%)       10 (9.0%)     0.508
   Rentrop collateral grade                                                                                                                      
    Grade 0                                         10 (6.4%)                  11 (6.6%)                0.937       7 (6.3%)        9 (8.1%)      0.604
    Grade 1                                        43 (27.4%)                 25 (13.8%)                0.002      20 (18.0%)      22 (19.8%)     0.732
    Grade 2                                        50 (31.8%)                 88 (52.7%)               \< 0.001    47 (42.3%)      46 (41.4%)     0.892
    Grade 3                                        54 (34.4%)                 45 (26.9%)                0.146      37 (33.3%)      34 (30.6%)     0.666
   Mean total stent length, mm                     40.1 ± 19.4                42.3 ± 22.1               0.348      40.8 ± 19.6     39.5 ± 21.8    0.620
   Mean stent diameter, mm                         2.79 ± 0.4                 2.88 ± 1.7                0.539      2.80 ± 0.2      2.81 ± 0.1     0.810
   Discharge medications                                                                                                                         
   Beta-blockers                                   82 (52.2%)                 85 (50.9%)                0.811      54 (48.6%)      59 (53.2%)     0.502
   CCB-DHP                                         18 (11.5%)                 34 (20.4%)                0.029      15 (13.5%)      24 (21.6%)     0.112
   CCB-NDHP                                        60 (28.3%)                 62 (37.1%)                0.840      51 (45.9%)      43 (38.7%)     0.277
   ACEI                                            62 (39.5%)                 59 (35.3%)                0.439      34 (30.6%)      40 (36.0%)     0.393
   ARB                                             49 (31.2%)                 48 (28.7%)                0.628      39 (35.1%)      29 (26.1%)     0.145
   Lipid lowering agents                           139 (88.5%)                154 (92.2%)               0.260      96 (86.5%)      100 (90.1%)    0.404
   Diuretics                                       35 (22.3%)                 37 (22.2%)                0.976      22 (19.8%)      25 (22.5%)     0.622

Data are presented as means ± SD or *n* (%). The *P*-value for continuous data from analysis of variance. The *P*-value for categorical data from chi-square test. ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; CCB-DHP: calcium channel blockers-dihydropyridine; CCB-NDHP: calcium channel blockers-non-dihydropyridine; CK-MB: creatine kinase myocardial band; CTO: chronic total occlusion; HDL: high-density lipoprotein; LDL: low-density lipoprotein; LVEF: left ventricular ejection fraction; MI: myocardial infarction; PCI: percutaneous coronary intervention; 1G-DES: first-generation drug-eluting stents; 2G-DES: second-generation drug-eluting stents.

###### Clinical outcomes by Kaplan--Meier curved analysis and Cox-proportional hazard ratio analysis.

  Outcomes                                Cumulative Events at five years   HR (95% CI)   *P*-value                         
  -------------------------------------- --------------------------------- ------------- ----------- ---------------------- -------
  Entire Patients                                                                                                           
   MACE                                             42 (26.8%)              24 (18.2%)      0.065     1.600 (0.966--2.651)   0.068
    All-cause death                                  5 (3.2%)                5 (3.6%)       0.870     0.901 (0.259--3.137)   0.870
    Cardiac death                                    3 (1.9%)                2 (1.2%)       0.663     1.485 (0.248--8.901)   0.665
   Re-MI                                             4 (2.6%)                1 (0.6%)       0.169     4.127 (0.461--36.96)   0.205
   Total repeat revascularization                   38 (24.5%)              20 (16.1%)      0.048     1.719 (0.997--2.965)   0.051
    Target lesion (TLR-CTO vessel)                  23 (14.9%)              13 (10.7%)      0.213     1.540 (0.776--3.057)   0.217
    Target vessel (TVR-CTO vessel)                  28 (18.1%)              15 (12.0%)      0.094     1.703 (0.906--3.202)   0.099
    Non-target vessel (Non-CTO vessel)              18 (11.7%)               10 (8.6%)      0.242     1.584 (0.728--3.119)   0.246
  Propensity score-matched Patients                                                                                         
   MACE                                             25 (22.5%)              15 (15.9%)      0.172     1.557 (0.820--2.959)   0.176
    All-cause death                                  3 (2.7%)                4 (4.0%)       0.624     0.689 (0.154--3.087)   0.626
    Cardiac death                                    2 (1.8%)                1 (0.9%)       0.596     1.893 (0.171--20.90)   0.603
   Re-MI                                             2 (1.8%)                1 (0.9%)       0.562     2.006 (0.182--22.12)   0.570
   Total repeat revascularization                   23 (21.1%)              12 (13.5%)      0.104     1.774 (0.881--3.572)   0.109
    Target lesion (TLR-CTO vessel)                  12 (11.0%)               7 (7.9%)       0.345     1.564 (0.614--3.982)   0.349
    Target vessel (TVR-CTO vessel)                  16 (14.7%)               8 (8.9%)       0.132     1.902 (0.812--4.453)   0.138
    Non-target vessel (Non-CTO vessel)              13 (12.0%)               8 (9.5%)       0.443     1.411 (0.583--3.416)   0.445

CTO: chronic total occlusion; HR: hazard ratio; MACE: major adverse cardiac event; Re-MI: recurrent myocardial infarction; TLR: target lesion revascularization; TVR: target vessel revascularization; 1G-DES: first-generation drug-eluting stents; 2G-DES: second-generation drug-eluting stents.

![Kaplan-Meier curved analysis of MACE (A & B), TLR-CTO vessel (C & D), TVR-CTO (E & F) according to the generation of DES (1G-DES *vs.* 2G-DES) and the types of DES (SES *vs.* PES *vs.* ZES *vs.* EES) up to 5-year after PSM.\
CTO: chronic total occlusion; DES: rug-eluting stent; EES: everolimus-eluting stent; MACE: major adverse cardiac event; PES: paclitaxel-eluting stent; PSM: propensity-score matched analysis; SES: sirolimus-eluting stent; TLR: target lesion revascularization; TVR: target vessel revascularization; 1G-DES: first-generation drug-eluting stents; 2G-DES: second-generation drug-eluting stents.](jgc-16-08-639-g002){#jgc-16-08-639-g002}

4. Discussion {#s4}
=============

The main finding of this study was that the cumulative incidence of MACE defined as the composite of all-cause death, non-fatal MI, repeat revascularization (TLR, TVR, and Non-TVR) was not significantly different between the 1G-DES and the 2G-DES following successful CTO PCI up to 5-year follow-up period.

2G-DES have relatively thin stent struts and biocompatible polymers which improved stability. Lipotropism of eluting drugs lead to reduced endothelial damage and proliferations compared with 1G-DES.[@b20],[@b21] In addition to previous studies which showing superiority of 2G-DES in the occurrence of MI, TLR and stent thrombosis over 1G-DES, recently a large meta-analysis also showed better efficacy and safety of 2G-DES compared to 1G-DES.[@b22] According this report, 2G-DES were associated with lower incidence of death \[odds ratio (OR) = 0.37, 95% CI: 0.15--0.91\], TVR (OR = 0.59, 95% CI: 0.40--0.87), and reocclusion (OR = 0.35, 95% CI: 0.17--0.71) compared to 1G-DES. By contrast, the comparative results between 1G-DES and 2G-DES in CTO lesions were also reported. Ahn, *et al*.[@b15] reported that the efficacy of 2G-DES is comparable to 1G-DES for treating CTO up to 2-year follow-up periods. The cumulative incidence of MACE (HR = 0.93, 95% CI: 0.63--1.37, *P* = 0.71) were not significantly different between 1G-DES (SES or PES) and 2G-DES (ZES or EES). Cho, *et al*.[@b16] also reported similar clinical outcomes between 1G-DES and 2G-DES up to 3-year follow-up periods. In that report, the composite of death, Q-wave MI, or TVR (HR = 1.42, 95% CI: 0.69--2.56, *P* = 0.39) were similar between the two groups.

In our study, up to 5-year follow-up periods, the cumulative incidences MACE was similar between the two groups before and after PSM. The results of Kaplan-Meier analysis for MACE, TLR and TVR among SES, PES, ZES, and EES were not statistically different ([Figure 2](#jgc-16-08-639-g002){ref-type="fig"}). These results were similar with previous reports.[@b13],[@b16],[@b23],[@b24] Moreno, *et al*.[@b13] reported that in the CTO patients, EES is as effective as SES during 1-year follow-up period. The cumulative incidence of MACE rates was 15.9% versus 11.1% with SES and EES and the rate of binary restenosis was also similar (10.8% *vs.* 9.1%, *P* = 0.709) in their study. Machado, *et al*.[@b25] reported 1G-DES and 2G-DES seem to be similarly effective in patients after PCI in the setting of acute coronary syndrome. During mean follow-up 598 days, the composite primary end point (all-cause death, non-fatal MI, TVR) of their study was not significantly different (10.8% *vs.* 12.2%, *P* = 0.463) between 1G-DES and 2G-DES. By contrast, there were some different reports were also reported in patients with acute coronary syndrome.[@b26],[@b27] These debates were also reported in patients with coronary bifurcation lesions.[@b28]--[@b30] Current guidelines do not recommend specific type of DES between these two groups of DES during PCI.[@b31] Because our study\'s follow-up periods were much longer than previous studies, the results of our study may provide a meaningful message especially, in a situation where there was rare long-term clinical outcome data between the 1G-DES and the 2G-DES after successful CTO PCI.

In the entire patients, five cases of stent thrombosis (5/324, 1.5%) were occurred up to 5-year follow-up periods. But the comparative cumulative incidence of stent thrombosis was statistically insignificant (*P* = 0.202). Among them four cases (1 SES and 3 PES) of stent thrombosis were occurred in 1G-DES (2.5%) and one case (1 EES) was in 2G-DES (0.6%). In the 1G-DES group, one case was acute stent thrombosis (occurring between 0 and 24 hours after stent implantation) and another one case was subacute stent thrombosis (occurring between 24 hours and 30 days) and other two cases were very late stent thrombosis (occurring after one year). In the 2G-DES group, only one case of stent thrombosis was occurred and was regarded as a very late stent thrombosis. Because only one case was included in our study after PSM, we excluded stent thrombosis from our outcome parameter inevitably.

Until today, in spite of comparative advantages of 2G-DES over 1G-DES such as stent platform which have more thinner, improved deliverability and flexibility and have reduced inflammatory reaction and improved re-endothelization, the reasons for why the long-term clinical outcomes were similar between the two groups were not thoroughly illuminated. To find out more detailed causative factors that can affect these results, more large scaled long-term randomized control study might be required.

4.1. Limitations {#s4a}
----------------

This study has some limitations. Firstly, because of non-randomized, single center registry design of this study, several confounding factors such as under-reporting and/or missing value and selection bias may have affected the end results. Secondly, although PSM analysis was done, the proportions of the different stent types in the both groups were not evenly distributed. Thirdly, even though this study\'s follow-up periods were longer than previous study, the total numbers of included patients were relatively small to compare the individual and composite clinical outcomes. Last but not least, until today, newly developed CTO guidewire or devices may be more frequently used in 2D-DES group compared to 1G-DES, these factors can affect the outcomes of this study.

4.2. Conclusions {#s4b}
----------------

In conclusion, in our single-center, all-comer registry, 2G-DES was not associated with reduced long-term MACE compared with 1G-DES following successful CTO revascularization up to five years possibility due to limited number of the study population.
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